Eden Biodesign Limited, (Liverpool, UK, www.edenbiodesign.com), and Borean Pharma (Aarhus, Denmark, www.boreanpharma.com), have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in preclinical studies.
Eden Biodesign Limited, (Liverpool, UK, www.edenbiodesign.com), and Borean Pharma (Aarhus, Denmark, www.boreanpharma.com), have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in preclinical studies. The project is expected to be completed early in 2008.
MBP-DC-SIGN is a Borean product based on its mannose-binding protein platform, which delivers a series of highly potent therapeutics for the treatment of cancers. It is the only scaffold that can induce complement-induced lysis.
